| Форма представления | Тезисы и материалы конференций в зарубежных журналах и сборниках |
| Год публикации | 2018 |
|
Гусев Олег Александрович, автор
Шагимарданова Елена Ильясовна, автор
|
| Другие авторы |
Никитин Алексей Георгиевич |
|
Ананьева Анастасия Викторовна, автор
Шигапова Лейля Хуззатовна, автор
|
| Библиографическое описание на языке оригинала |
Ananeva, A. Genetic testing to guide warfarin dosage in Russian Federation / A.Ananeva, L.Shigapova, A.Nikitin, M.Gordiev, E.Shagimardanova // Abstracts of the 52nd Annual Scientific Meeting of the European Society for Clinical Investigation "Precision medicine for healthy ageing". - 2018. - V.48. - I.1. - P.135. |
| Аннотация |
Warfarin is widely prescribed anticoagulant in thromboembolic disorders, that acts by reducing the activity of vitamin K-dependent clotting
factors. The dose of warfarin should be adapted for each patient, based on individual properties and measurements: weight, height, ethnic
background and presence of SNPs in genes involved in warfarin metabolism. In this study, we aimed to determine the frequency of
clinically relevant SNP in CYP2C9 and VKORC1 in population of Tatarstan region in Russian Federation. |
| Ключевые слова |
warfarin, polymorphism, next-generation sequencing (NGS) |
| Место издания |
Барселона |
| Издательство |
John Wiley & Sons Ltd |
| URL |
https://onlinelibrary.wiley.com/toc/13652362/2018/48/S1 |
| Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку |
https://repository.kpfu.ru/?p_id=182660 |
Полная запись метаданных  |
| Поле DC |
Значение |
Язык |
| dc.contributor.author |
Гусев Олег Александрович |
ru_RU |
| dc.contributor.author |
Шагимарданова Елена Ильясовна |
ru_RU |
| dc.contributor.author |
Ананьева Анастасия Викторовна |
ru_RU |
| dc.contributor.author |
Шигапова Лейля Хуззатовна |
ru_RU |
| dc.date.accessioned |
2018-01-01T00:00:00Z |
ru_RU |
| dc.date.available |
2018-01-01T00:00:00Z |
ru_RU |
| dc.date.issued |
2018 |
ru_RU |
| dc.identifier.citation |
Ananeva, A. Genetic testing to guide warfarin dosage in Russian Federation / A.Ananeva, L.Shigapova, A.Nikitin, M.Gordiev, E.Shagimardanova // Abstracts of the 52nd Annual Scientific Meeting of the European Society for Clinical Investigation "Precision medicine for healthy ageing". - 2018. - V.48. - I.1. - P.135. |
ru_RU |
| dc.identifier.uri |
https://repository.kpfu.ru/?p_id=182660 |
ru_RU |
| dc.description.abstract |
Warfarin is widely prescribed anticoagulant in thromboembolic disorders, that acts by reducing the activity of vitamin K-dependent clotting
factors. The dose of warfarin should be adapted for each patient, based on individual properties and measurements: weight, height, ethnic
background and presence of SNPs in genes involved in warfarin metabolism. In this study, we aimed to determine the frequency of
clinically relevant SNP in CYP2C9 and VKORC1 in population of Tatarstan region in Russian Federation. |
ru_RU |
| dc.language.iso |
ru |
ru_RU |
| dc.publisher |
John Wiley & Sons Ltd |
ru_RU |
| dc.subject |
warfarin |
ru_RU |
| dc.subject |
polymorphism |
ru_RU |
| dc.subject |
next-generation sequencing (NGS) |
ru_RU |
| dc.title |
Title Genetic testing to guide warfarin dosage in Russian Federation |
ru_RU |
| dc.type |
Тезисы и материалы конференций в зарубежных журналах и сборниках |
ru_RU |
|
EN 
中文 
ES 
Карта сайта
